GW to file cannabis drug as journal confirms epilepsy success

GW Pharmaceuticals is set to file its cannabis-derived drug with U.S. regulators imminently, following publication of detailed data on its success in fighting severe childhood epilepsy.GW first reported in March 2016 that Epidiolex cut monthly convulsive seizures by 39 percent in children with Dravet syndrome, but full results of the 120-patient study were only published in the New England Journal of Medicine on Wednesday.GW's medicine, which is given as a syrup, is a purified form of cannabidio